Article Text

PDF
Gastric cancer: somatic genetics as a guide to therapy
  1. Xiao-ying Zhang1,
  2. Pei-ying Zhang2,3,4,5
  1. 1Nanjing University of Chinese Medicine, Information Institute, Nanjing, Jiangsu, China
  2. 2Xuzhou Central Hospital, Xuzhou, Jiangsu Province, China
  3. 3The Affiliated XuZhou Hospital of Medical College of Southeast University, Xuzhou, Jiangsu Province, China
  4. 4Xuzhou Clinical School of Xuzhou Medical College, Xuzhou, Jiangsu Province, China
  5. 5Xuzhou Clinical Medical College of Nanjing University of Chinese Medicine, Xuzhou, Jiangsu Province, China
  1. Correspondence to Dr Peiying Zhang, Xuzhou Central Hospital, Xuzhou, Jiangsu Province 221009, China; zpying58{at}126.com

Abstract

Gastric cancer is the leading cause of cancer-related mortality across the world, with poor prognosis and a median overall survival of ≤12 months for advanced stage gastric cancer. Environmental, genetic and other predisposing factors contribute to the development of gastric cancer and a predominant factor was found to be infection of Helicobacter pylori. Advances in understanding the deranged signalling pathways that are critical for normal cellular homeostasis helped in the development of novel drugs that target specific proteins and pathways to curtail the growth of gastric cancer. Genetic studies revealed several single nucleotide polymorphisms, chromosomal aberrations and epigenetic alterations that likely play a major role in elevating the susceptibility to develop gastric cancer. Methylation pattern of specific genes may likely prove to be a valid biomarker for early detection of gastric cancer, but much progress is needed to establish specific markers. Important developments have been made in targeting human epidermal growth factor receptor-2 and vascular endothelial growth factor receptor 2 for treating advanced gastro-oesophageal junction cancer, using specific monoclonal antibodies. Lack of efficacy with regard to targeting other signalling pathways including mesenchymal-epithelial transition/hepatocyte growth factor and mammalian target of rapamycin is probably due to suboptimal patient selection for these clinical trials, which is probably due to the lack of appropriate biomarkers, to decide on responsive patient population. Besides the development of antagonists for the cell growth-related signalling pathways, advances are also being made to tackle gastric cancer by immunotherapies, targeting immune check-points, which may hold promise for better treatment options in future.

  • Cancer: gastric
  • Cancer: oesophageal
  • Epigenetics
  • Genetics
  • Stomach and duodenum

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.